Catalog No.
DHD80804
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28907
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MOR-03087, CAS: 2197112-39-1
Clone ID
Felzartamab
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial, PMID: 32171061
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond, PMID: 32531894
Targeting CD38 in Antibody-Mediated Rejection., PMID:40444214
Antibody-mediated Rejection - Treatment Standard., PMID:40440205
Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies., PMID:40301559
Microvascular inflammation in kidney allografts: New directions for patient management., PMID:40199388
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation., PMID:39925214
Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system., PMID:39674514
Enhanced Prenatal and Postnatal Development Study in Marmoset Monkeys Following Administration of Felzartamab., PMID:39526914
Felzartamab in Antibody-Mediated Rejection. Reply., PMID:39321372
Felzartamab in Antibody-Mediated Rejection., PMID:39321371
Felzartamab in Antibody-Mediated Rejection., PMID:39321370
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy., PMID:39291206
Chronic Rejection After Kidney Transplantation., PMID:39192468
Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series., PMID:39149569
Felzartamab and Antibody-Mediated Rejection in Kidney Transplants - Hope at Last?, PMID:38986063
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection., PMID:38804514
Future landscape for the management of membranous nephropathy., PMID:37529655
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy., PMID:37183663
Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?, PMID:36707937
Emerging strategies for antibody-mediated rejection., PMID:35950889
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials., PMID:35715978
Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study., PMID:35702397
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial., PMID:35395951
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma., PMID:33353443
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond., PMID:32531894
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial., PMID:32171061
For research use only. Not for human or drug use.
